These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 25337766)
1. Novel mutations in a patient with ALK-rearranged lung cancer. Giri S; Patel JK; Mahadevan D N Engl J Med; 2014 Oct; 371(17):1655-6. PubMed ID: 25337766 [No Abstract] [Full Text] [Related]
2. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors. Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586 [TBL] [Abstract][Full Text] [Related]
3. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry. Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446 [No Abstract] [Full Text] [Related]
4. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. Costa DB; Kobayashi S J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013 [No Abstract] [Full Text] [Related]
5. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444 [No Abstract] [Full Text] [Related]
6. Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. van Geffen WH; Hiltermann TJ; Groen HJ J Thorac Oncol; 2013 Jan; 8(1):e1-2. PubMed ID: 23242444 [No Abstract] [Full Text] [Related]
8. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628 [TBL] [Abstract][Full Text] [Related]
9. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824 [No Abstract] [Full Text] [Related]
10. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522 [TBL] [Abstract][Full Text] [Related]
11. Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation. Toyokawa G; Takenoyama M; Watanabe S; Toyozawa R; Inamasu E; Kojo M; Shiraishi Y; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Ichinose Y J Thorac Oncol; 2013 Nov; 8(11):e96-8. PubMed ID: 24128725 [No Abstract] [Full Text] [Related]
12. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H; N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473 [TBL] [Abstract][Full Text] [Related]
13. Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance. Schrödl K; von Schilling C; Tufman A; Huber RM; Gamarra F Respiration; 2014; 88(3):262-4. PubMed ID: 25115320 [TBL] [Abstract][Full Text] [Related]
15. More than just an oncogene translocation and a kinase inhibitor: Kevin's story. Costa DB J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391 [No Abstract] [Full Text] [Related]
16. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764 [TBL] [Abstract][Full Text] [Related]
17. Treatment and detection of ALK-rearranged NSCLC. Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207 [TBL] [Abstract][Full Text] [Related]
18. Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. Toyokawa G; Inamasu E; Shimamatsu S; Yoshida T; Nosaki K; Hirai F; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y J Thorac Oncol; 2015 Jul; 10(7):e55-7. PubMed ID: 26134233 [No Abstract] [Full Text] [Related]
19. Oncologists push beyond new lung cancer genomic testing guidelines. Garber K J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25677038 [No Abstract] [Full Text] [Related]
20. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]